Research and Markets: Psoriasis - Thought Leader Panel 2012 - A Summary of Persepectives from 6 Key Opinion Leaders

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/2r4sgn/psoriasis_thought) has announced the addition of the "Psoriasis Thought Leader Panel #22 2012-04" report to their offering.

Psoriasis Thought Leader Panel #22 summarizes the perspectives of 6 key opinion leaders who had attended Gene to Clinic (London), AAD, or both in 1Q2012, supplemented with comments from Panel #21 and publicly available data on key drugs in development.

The Panel Weighs in On:

- The pros and cons of sequencing IL23, IL17, JAK, other orals and topicals against their established 1st line biologicals.

- Increases and decreases in cardiovascular events associated with inhibitors of TNF, IL23, IL17 and IL12.

- Advantages/disadvantages of IL23/IL12 vs p19 inhibitors.

- Advantages of a pure IL12 inhibitor

- Advantages/drawbacks for broad vs subreceptor selective IL17 approaches.

- Combinations and immunosuppression

- PDE4 inhibitors - less efficacious by PASI, but do they have other unique benefits?

- Toll-like receptors

- IL22

This report also has an appendix, which contains the data from our Fantasy Formulary exercise, conducted at the end of 2011. In this ranking exercise, Panelists had an opportunity to choose the most intriguing new therapeutics based on their perception of each product's combined benefit profile.

Key Topics Covered:

Executive Summary

Key Findings

- Commercial Opportunity for the New Psoriasis Therapies

- Innate Immunity

- TNF

-- Enbrel (etanercept; Amegen)

-- Humira (adalimumab; Abbott)

-- Cimzia (certolizumab; UCB)

-- COVA-301 (Covagen / Roche)

- IL-23

-- Stelara (ustekinumab; CNTO-1275; Janssen; Merck; Essex)

-- MK3222 / SCH900222 (p19, IL-23 selective MAb; Merck / Schering-Plough) DNAX

-- CNTO 1959 P19, IL-23 selective; Janssen / Morphosys)

-- briakinumab (Abbott)

-- ILY2525623 (Lilly)

- IL-17

-- brodalumab AMG-827 (Amegen/AstraZeneca)

-- AIN-457 (secukinumab; Novartis)

-- ixekizumab LY2439821 (Lilly)

- JAK inhibitors

-- tofacitinib (tasocitinib; CP-690550; Pfizer)

-- INCB-28050 / LY-3009104 (incyte / Lilly)

- Topical JAK Inhibitors

-- INCB-18424 (incyte)

-- tofacitinib (Pfizer)

-- "Pure" JAK 3 Inhibitors

-- ASP015K (Astellas)

-- VX-509 (Vertex)

- PDE-4

-- Apremilast (a.k.a. CC-100044; Celgene)

-- AN-2728 (Anacor)

- PKC

-- sotrastaurin; NVP-aeb-071 (Novartis)

- IL-12

-- VB-201 (Vascular Biogenics)

- Toll-Like Receptor 7,9

-- IMO-3100(Idera)

- IL-22

-- Fezakinumab (ILV-094) anti-IL22 MAb (Pfizer / Wyeth)

- CD40

-- ASKP1240 (Astellas)

Appendix 1 Fantasy Formulary Results

- Methods

- Results

-- Table 1*: 2011 Composite Scores by Drug Classes

-- Table 2: 2011 Composite Scores for all Drugs Mentioned

Thought Leader Discussions

- Interview OHIIDO2685

- Interview OHIIDO2686

- Interview OHIIDO2687

- Interview OHIIDO2688

- Interview OHIIDO2689

- Interview OHIIDO2690

Companies Mentioned:

- Abbott (Eisai)

- Amgen / AstraZeneca

- Amgen / Pfizer

- Anacor

- Astellas

- Celgene

- Covagen / Roche

- Idera

- Incyte

- Incyte / Lilly

- Janssen / Merck / Essex

- Janssen / Morphosys

- Lilly

- Merck

- Novartis

- Pfizer

- UCB

- Vascular Biogenics

- Vertex

For more information visit http://www.researchandmarkets.com/research/2r4sgn/psoriasis_thought